FAP and neoplasm: This could be solved by the addition of an albumin binder to the pyridine-based FAP-targeted ligands to extend their blood residence time as similar approaches have been exploited to Increase the tumor uptake of radiolabeled quinoline-based FAPI-04 derivatives [34,35].